论文部分内容阅读
目的:探讨阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床疗效及对患者肺功能的影响。方法:选取2013年6月-2016年3月我院收治的慢性阻塞性肺疾病合并肺动脉高压患者107例,根据治疗方法不同分为对照组(49例)与实验组(58例)。对照组患者采用阿奇霉素治疗,实验组患者在对照组基础上给予辛伐他汀治疗。观察并比较两组患者的临床疗效、不良反应以及肺功能指标的变化情况。结果:实验组患者治疗有效率(87.93%)高于对照组(73.47%),差异具有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后1 s用力呼吸容积(FEV1)、用力肺活量(FVC)及FEV1/FVC水平均升高,差异具有统计学意义(P<0.05);与对照组比较,实验组患者治疗后1 s用力呼吸容积(FEV1)、用力肺活量(FVC)及FEV1/FVC水平较高,差异具有统计学意义(P<0.05)。治疗后,两组患者血清总胆固醇(TC)及三酰甘油(TG)水平均降低,差异具有统计学意义(P<0.05);与对照组比较,实验组患者治疗后血清总胆固醇(TC)及三酰甘油(TG)水平较低,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿奇霉素联合辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床效果显著,不仅能够改善患者肺功能,降低血脂相关指标水平,并且安全性较高,值得临床推广应用。
Objective: To investigate the clinical effect of azithromycin combined with simvastatin on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and its effect on pulmonary function. Methods: A total of 107 patients with chronic obstructive pulmonary disease and pulmonary hypertension admitted to our hospital from June 2013 to March 2016 were selected and divided into control group (49 cases) and experimental group (58 cases) according to different treatment methods. Patients in the control group were treated with azithromycin. Patients in the experimental group were given simvastatin on the basis of the control group. The clinical efficacy, adverse reactions and changes of lung function indexes of the two groups were observed and compared. Results: The effective rate of treatment group (87.93%) was higher than that of control group (73.47%), the difference was statistically significant (P <0.05). Compared with those before treatment, the FEV1, FVC and FEV1 / FVC levels of two groups were significantly increased after treatment (P <0.05). Compared with the control group, The forced expiratory volume (FEV1), forced vital capacity (FVC) and FEV1 / FVC level were significantly higher in group 1 after treatment (P <0.05). After treatment, the levels of total cholesterol (TC) and triglyceride (TG) in both groups decreased, with statistical significance (P <0.05). Compared with the control group, the levels of total cholesterol (TC) And triglyceride (TG) levels were lower, the difference was statistically significant (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion: The combination of azithromycin and simvastatin has significant clinical effect in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension, which not only can improve pulmonary function and reduce the level of serum lipids, but also has high safety. It is worthy of clinical application.